Skip to main content
main-content

ESMO Congress 2021 coverage

NEWS AND EXPERT VIDEO INTERVIEWS FROM THE MEETING

Expert video interviews

29-09-2021 | ESMO 2021 | Conference coverage | Video

Dual EphrinB2 pathway, PD-1 inhibition shows promise in metastatic UC setting

Sarmad Sadeghi talks about their phase 2 trial pointing to the potential of combining the novel EphrinB2 pathway inhibitor sEphB4-HSA with pembrolizumab in previously treated patients with metastatic urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

28-09-2021 | ESMO 2021 | Conference coverage | Video

ctDNA analysis may help to personalize metastatic urothelial carcinoma treatments

Guru Sonpavde outlines the findings of their immunotherapy study supporting a potential role for longitudinal ctDNA profiling to identify suitable therapies for people with metastatic urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

18-09-2021 | ESMO 2021 | Conference coverage | Video

Promising early results for cetrelimab plus erdafitinib reported for advanced UC

Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Latest research news | Breast cancer

Latest research news | COVID-19

Latest research news | Genitourinary cancers

Latest research news | Thoracic cancers

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


Medicine Matters conference coverage is brought to you in partnership with medwireNews



Image Credits